Effect of Chaishao Jieyu Decoction combined with Pingxiao Capsule on the patients with luminal breast cancer after operation

Objective:To study the improvement of Chaishao Jieyu decoction combined with Pingxiao capsule on the mental state、immune function and endometrium of patients with luminal breast cancer undergoing endocrine therapy after operation.Methods:60 cases of luminal breast cancer patients after operation,according to the method of random grouping would be divided into the control group and the observation group,each group 30 cases.The control group were treated with tamoxifen.On the basis,the observation group accepted oral administration of Chaishao Jieyu Decoction and Pingxiao capsule.The levels of 5-HT、DA、T lymphocyte subsets、IGF-1 and endometrial thickness were compared.Results:At the end of treatment,the observation group's 5-HT、DA、CD3+、CD4+levels were obviously higher than the control group(P<0.05),the observation group's CD8+levels、IGF-1 levels and endometrial thickness were significantly lower than the control group(P<0.05).Conclusion:Chaishao Jieyu Decoction combined with Pingxiao capsule can significantly improve the mental state、immune function of patients with luminal breast cancer undergoing endocrine therapy after surgery,and inhibit their endometrial thickening,the effect is exact.

Type IV collagen α5 chain promotes luminal breast cancer progression through c-Myc-driven glycolysis

Cancer cell metabolism reprogramming is one of the hallmarks of cancer.Cancer cells preferentially utilize aerobic glycolysis,which is regulated by activated oncogenes and the tumor microenvironment.Extracellular matrix(ECM)in the tumor microenvironment,including the basement membranes(BMs),is dynamically remodeled.However,whether and how ECM regulates tumor glycolysis is largely unknown.We show that type IV collagens,components of BMs essential for the tissue integrity and proper function,are differentially expressed in breast cancer subtypes thatα5 chain(α5(IV))is preferentially expressed in the luminal-type breast cancer and is regulated by estrogen receptor-α.α5(IV)is indispensable for luminal breast cancer development.Ablation ofα5(IV)significantly reduces the growth of luminal-type breast cancer cells and impedes the development of luminal-type breast cancer.Impaired cell growth and tumor development capability ofα5(IV)-ablated luminal breast cancer cells is attributed to the reduced expression of glucose transporter and glycolytic enzymes and impaired glycolysis in luminal breast cancer cells.Non-integrin collagen receptor discoidin domain receptor-1(DDR1)expression and p38 mitogen-activated protein kinase activation are attenuated inα5(IV)-ablated luminal breast cancer cells,resulting in reduced c-Myc oncogene expression and phosphorylation.Ectopic expression of constitutively active DDR1 or c-Myc restores the expression of glucose transporter and glycolytic enzymes,and thereafter restores aerobic glycolysis,cell proliferation,and tumor growth of luminal breast cancer.Thus,type IV collagenα5 chain is a luminal-type breast cancer-specific microenvironmental regulator modulating cancer cell metabolism.

Significance of serum carcinoembryonic antigen in metastatic breast cancer patients:A prospective study

BACKGROUND Carcinoembryonic antigen(CEA)is an important serum tumour marker with a substantial role in diagnosis and monitoring of various solid tumours.About 36%-70%of breast cancers have elevated serum CEA.And the available studies show discrepancy in addressing the prognostic significance of CEA in advanced breast cancer.AIM To estimate the serum CEA level in our metastatic breast cancer patients and correlate it with response to treatment and clinical outcome.METHODS This was a prospective clinical study conducted on 50 metastatic breast cancer patients treated at breast clinic,with newly diagnosed metastatic breast cancer planned for palliative chemotherapy,targeted therapy,and hormonal treatment.We estimated the proportion of patients with elevated serum CEA level at baseline and after palliative treatment and also studied the association of serum CEA levels with known prognostic factors.The response to treatment was correlated with the serum CEA levels in the context of responders and nonresponders.RESULTS The median pre-treatment and post-treatment CEA levels were 7.9(1.8-40.7)ng/mL and 4.39(1.4-12.15)ng/mL,respectively,in the whole study population(P=0.032).No statistically significant difference was seen in baseline serum CEA between responders and non-responders.Even in the luminal group,pretreatment serum CEA was not a predictor of response,but post-treatment CEA was a significant predictor of tumour progression.In patients with liver and lung metastases,post-treatment CEA level difference was not statistically significant in both responders and non-responders though the values were higher in nonresponders.Among those with bone metastases,69.5%had elevated post-treatment serum CEA,and only 37.5%had elevated serum CEA in those with no bone metastases.CONCLUSION Elevated post-treatment serum CEA levels are associated with disease progression and poor response to therapy.Persistently elevated post-treatment serum CEA levels are significantly associated with bone metastases.Elevated serum CEA and hormonal status are significant predictors of treatment response.